MX2020005850A - Sales de fosforamidato de difosfato de nucleosidos como compuestos anticancerigenos. - Google Patents

Sales de fosforamidato de difosfato de nucleosidos como compuestos anticancerigenos.

Info

Publication number
MX2020005850A
MX2020005850A MX2020005850A MX2020005850A MX2020005850A MX 2020005850 A MX2020005850 A MX 2020005850A MX 2020005850 A MX2020005850 A MX 2020005850A MX 2020005850 A MX2020005850 A MX 2020005850A MX 2020005850 A MX2020005850 A MX 2020005850A
Authority
MX
Mexico
Prior art keywords
nucleosides
salts
anticancer compounds
phosphoramidate
diphosphate
Prior art date
Application number
MX2020005850A
Other languages
English (en)
Spanish (es)
Inventor
Hugh Griffith
Michaela Serpi
Fabrizio Pertusati
Magdalena Slusarczyk
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuCana plc filed Critical NuCana plc
Publication of MX2020005850A publication Critical patent/MX2020005850A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MX2020005850A 2017-12-05 2018-12-05 Sales de fosforamidato de difosfato de nucleosidos como compuestos anticancerigenos. MX2020005850A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1720279.7A GB201720279D0 (en) 2017-12-05 2017-12-05 Anticancer compounds
PCT/GB2018/053525 WO2019110991A1 (en) 2017-12-05 2018-12-05 Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds

Publications (1)

Publication Number Publication Date
MX2020005850A true MX2020005850A (es) 2020-09-07

Family

ID=60950385

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005850A MX2020005850A (es) 2017-12-05 2018-12-05 Sales de fosforamidato de difosfato de nucleosidos como compuestos anticancerigenos.

Country Status (22)

Country Link
US (2) US11560400B2 (enExample)
EP (2) EP3720864B1 (enExample)
JP (1) JP7268819B2 (enExample)
KR (1) KR20200092980A (enExample)
CN (1) CN111527098A (enExample)
AU (1) AU2018379713A1 (enExample)
BR (1) BR112020011221A2 (enExample)
CA (1) CA3082269A1 (enExample)
CL (1) CL2020001479A1 (enExample)
DK (1) DK3720864T3 (enExample)
EA (1) EA202091218A1 (enExample)
ES (1) ES2910165T3 (enExample)
GB (1) GB201720279D0 (enExample)
HR (1) HRP20220451T1 (enExample)
IL (1) IL274808B2 (enExample)
MA (2) MA51007A (enExample)
MX (1) MX2020005850A (enExample)
PH (1) PH12020550728A1 (enExample)
PL (1) PL3720864T3 (enExample)
PT (1) PT3720864T (enExample)
SG (1) SG11202004342TA (enExample)
WO (1) WO2019110991A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20191461T1 (hr) 2014-11-28 2019-11-15 NuCana plc Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja
JP2020164521A (ja) * 2019-03-29 2020-10-08 国立大学法人 長崎大学 抗ウィルス薬
CN116768949B (zh) * 2022-07-12 2026-03-03 南京工业大学 一种基于3’-脱氧腺苷经化学修饰改性的具有抗癌效应的化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
WO2010135520A1 (en) 2009-05-20 2010-11-25 Chimerix, Inc. Compounds, compositions and methods for treating viral infection
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
ES2569185T3 (es) 2011-03-01 2016-05-09 Nucana Biomed Limited Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer
WO2014124430A1 (en) * 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
TW201542581A (zh) 2013-09-11 2015-11-16 艾默理大學 核苷酸與核苷治療組成物及其相關用途
CN105646629A (zh) 2014-11-25 2016-06-08 广州市恒诺康医药科技有限公司 L-核苷类化合物及其应用
HRP20191461T1 (hr) 2014-11-28 2019-11-15 NuCana plc Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja
WO2016099982A2 (en) * 2014-12-15 2016-06-23 Emory University Phosphoramidates for the treatment of hepatitis b virus
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2017106710A1 (en) 2015-12-17 2017-06-22 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2017155923A1 (en) 2016-03-07 2017-09-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609602D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds

Also Published As

Publication number Publication date
JP7268819B2 (ja) 2023-05-08
CL2020001479A1 (es) 2020-12-18
EP4043471A1 (en) 2022-08-17
AU2018379713A1 (en) 2020-07-23
DK3720864T3 (da) 2022-04-11
HRP20220451T1 (hr) 2022-05-27
PT3720864T (pt) 2022-04-06
KR20200092980A (ko) 2020-08-04
PH12020550728A1 (en) 2021-02-15
IL274808B2 (en) 2023-08-01
GB201720279D0 (en) 2018-01-17
US20210171566A1 (en) 2021-06-10
IL274808B1 (en) 2023-04-01
EP3720864B1 (en) 2022-01-05
CN111527098A (zh) 2020-08-11
IL274808A (en) 2020-07-30
MA51007A (fr) 2020-10-14
US20230192750A1 (en) 2023-06-22
MA51006A (fr) 2020-10-14
EA202091218A1 (ru) 2020-09-14
BR112020011221A2 (pt) 2020-11-17
JP2021505578A (ja) 2021-02-18
EP3720864A1 (en) 2020-10-14
PL3720864T3 (pl) 2022-05-02
ES2910165T3 (es) 2022-05-11
WO2019110991A1 (en) 2019-06-13
SG11202004342TA (en) 2020-06-29
US11560400B2 (en) 2023-01-24
CA3082269A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
PH12020551055A1 (en) Methods for treating filoviridae virus infections
ZA201807652B (en) Phosphoramidate nucleoside derivatives as anticancer agents
MX2015012633A (es) Diesteres de fosfonato nucleosido aciclico.
PH12015502799A1 (en) Substituted nucleosides, nucleotides and analogs thereof
GEP20237502B (en) B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
EA201692312A1 (ru) Продукты гемцитабина
PH12020550728A1 (en) Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
EP3331354A4 (en) NUCLEOSIDE PHOSPHORAMIDATE PRODRUCE FOR THE TREATMENT OF VIRAL DISEASES AND CANCER, METHODS OF PREPARATION THEREOF AND USE THEREOF
PH12017500944B1 (en) New 2` and/or 5` amino-acid ester phosphoramidate 3`-deoxy adenosine derivatives as anti-cancer compounds
PH12018500691B1 (en) Combination therapy
MX2018007782A (es) Forma cristalina de gemcitabina.
PH12021552357A1 (en) Salt of triphosphate phosphoramidates of nucleotides as anticancer compounds
HK40062992A (en) Salt of triphosphate phosphoramidates of nucleotides as anticancer compounds
EA202090269A2 (ru) Продукты гемцитабина
IN2014MU00625A (enExample)